Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Flu vaccination, as well as being effective to prevent seasonal influenza, decreases staff illness and absenteeism and reduces costs resulting from loss of productivity. Despite the effectiveness of flu vaccination, the seasonal coverage among healthcare workers is usually low. The aim of this retrospective observational study is to analyze the vaccination coverage rate among all employees (healthcare workers and administrative staff) of a large teaching hospital in Rome during the 2017-2018 influenza season, to perform a cost-consequence analysis of influenza vaccination (by evaluating the absenteeism due to illness in the epidemic period), and to assess the impact of vaccination in terms of both costs and sick days.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Vaccinated subjects | Healthcare workers that received quadrivalent split inactivated non-adjuvanted flu vaccine Fluarix Tetra in a single administration |
| |
| Unvaccinated subjects | Healthcare workers that did not received flu vaccine |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Flu Vaccine | Drug | Administration of quadrivalent split inactivated non-adjuvanted flu vaccine Fluarix Tetra |
|
| Measure | Description | Time Frame |
|---|---|---|
| Effectiveness of the quadrivalent vaccine | Effectiveness of the quadrivalent vaccine in reducing the number of working days lost due to influenza syndrome | 33 weeks |
| Economic impact of the quadrivalent vaccine | Economic impact (for the company and society) of vaccination as part of a vaccination campaign on the healthcare workers of the teaching hospital. | 33 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Expected economic savings for each one percentage point increase in vaccination coverage | Expected economic savings for each one percentage point increase in coverage on the health personnel of the teaching hospital | 33 weeks |
| Non-economic incentives for healthcare personnel who decide to vaccinate |
Not provided
Inclusion Criteria:
• Healthcare workers at Fondazione Policlinico Universitario "A.Gemelli" IRCCS
Exclusion Criteria:
• Healthcare workers not working at Fondazione Policlinico Universitario "A.Gemelli" IRCCS
Not provided
Not provided
Not provided
Not provided
The study population is represented by all employed healthcare workers of the FPG amounting to approximately 5000 (data provided by the Human Resources Department of the Hospital in December 2017).
The case group consists of all healthcare workers vaccinated in the 2017-2018 season at the specially designated facilities within the Teaching Hospital, filed on special registers.
The control group consists of healthcare workers who were not vaccinated in the 2017-2018 season at the specially designated facilities within the Teaching Hospital.
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Fondazione Policlinico Universitario "A.Gemelli" IRCCS | Rome | 00168 | Italy |
Not provided
| ID | Term |
|---|---|
| D007251 | Influenza, Human |
| ID | Term |
|---|---|
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
| D009976 | Orthomyxoviridae Infections |
| D012327 | RNA Virus Infections |
Not provided
Not provided
| ID | Term |
|---|---|
| D007252 | Influenza Vaccines |
| ID | Term |
|---|---|
| D014765 | Viral Vaccines |
| D014612 | Vaccines |
| D001688 | Biological Products |
| D045424 | Complex Mixtures |
Not provided
Not provided
Not provided
Not provided
Not provided
Non-economic incentives for healthcare personnel who decide to vaccinate, in view of the financial savings for the company, linked to increased vaccination coverage |
| 33 weeks |
| D014777 | Virus Diseases |
| D012140 | Respiratory Tract Diseases |